Free Trial

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Increases Holdings in Axon Enterprise, Inc $AXON

Axon Enterprise logo with Aerospace background

Key Points

  • UBS AM increased its stake in Axon Enterprise, Inc by 4.5%, acquiring an additional 24,132 shares during the first quarter, bringing its total holdings to 555,690 shares valued at approximately $292.27 million.
  • Axon reported a 32.6% year-over-year revenue increase for the last quarter, achieving a total revenue of $668.54 million and an EPS of $2.12, surpassing analysts' estimates.
  • Insider trading activity showed notable sales, with President Joshua Isner selling 15,919 shares for about $11.88 million, reflecting a 6.26% decrease in his holdings.
  • MarketBeat previews the top five stocks to own by October 1st.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 4.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 555,690 shares of the biotechnology company's stock after buying an additional 24,132 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned about 0.71% of Axon Enterprise worth $292,265,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. TCTC Holdings LLC increased its stake in shares of Axon Enterprise by 75.0% in the 1st quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 24 shares in the last quarter. Fourth Dimension Wealth LLC purchased a new stake in Axon Enterprise in the fourth quarter worth about $30,000. Bartlett & CO. Wealth Management LLC increased its stake in shares of Axon Enterprise by 132.0% during the first quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company's stock valued at $31,000 after purchasing an additional 33 shares in the last quarter. Banque Transatlantique SA purchased a new position in shares of Axon Enterprise during the first quarter valued at approximately $31,000. Finally, Catalyst Capital Advisors LLC purchased a new position in shares of Axon Enterprise during the first quarter valued at approximately $32,000. 79.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

AXON has been the topic of several recent research reports. JMP Securities upped their price target on Axon Enterprise from $725.00 to $825.00 and gave the stock a "market outperform" rating in a research note on Tuesday, July 22nd. Needham & Company LLC set a $870.00 target price on Axon Enterprise and gave the stock a "buy" rating in a report on Tuesday, August 5th. UBS Group restated a "neutral" rating and set a $840.00 price target (up from $820.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Craig Hallum raised Axon Enterprise from a "hold" rating to a "buy" rating and set a $900.00 price target for the company in a research report on Tuesday, August 5th. Finally, Northland Securities set a $800.00 price target on shares of Axon Enterprise in a research note on Tuesday, August 5th. Thirteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Axon Enterprise currently has an average rating of "Moderate Buy" and an average target price of $837.69.

View Our Latest Analysis on Axon Enterprise

Insider Activity

In other news, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $743.64, for a total value of $7,436,400.00. Following the transaction, the chief executive officer owned 3,043,982 shares in the company, valued at $2,263,626,774.48. This represents a 0.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jeffrey C. Kunins sold 7,891 shares of the company's stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $750.10, for a total value of $5,919,039.10. Following the completion of the sale, the insider owned 144,538 shares of the company's stock, valued at $108,417,953.80. This trade represents a 5.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 44,790 shares of company stock worth $34,304,947. Company insiders own 4.40% of the company's stock.

Axon Enterprise Stock Performance

NASDAQ AXON traded up $5.02 during trading hours on Friday, hitting $756.13. The company's stock had a trading volume of 303,694 shares, compared to its average volume of 461,020. Axon Enterprise, Inc has a 12 month low of $375.71 and a 12 month high of $885.91. The company's 50 day simple moving average is $761.10 and its two-hundred day simple moving average is $687.25. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.95 and a quick ratio of 2.71. The company has a market cap of $59.36 billion, a P/E ratio of 186.70, a price-to-earnings-growth ratio of 27.57 and a beta of 1.40.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.54 by $0.58. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The firm had revenue of $668.54 million for the quarter, compared to the consensus estimate of $641.77 million. During the same quarter last year, the firm posted $1.20 EPS. The business's quarterly revenue was up 32.6% compared to the same quarter last year. Axon Enterprise has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Axon Enterprise Profile

(Free Report)

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

Read More

Institutional Ownership by Quarter for Axon Enterprise (NASDAQ:AXON)

Should You Invest $1,000 in Axon Enterprise Right Now?

Before you consider Axon Enterprise, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axon Enterprise wasn't on the list.

While Axon Enterprise currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.